Literature DB >> 11508393

Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.

M Simmons1, G S Murphy, C G Hayes.   

Abstract

Recombinant proteins containing the B domain of dengue virus serotypes 1-4 fused to the maltose binding protein (MBP) of Escherichia coli were evaluated individually and as a tetravalent vaccine candidate in mice. Sera from mice immunized with monovalent DEN-MBP recombinant protein vaccines developed high titers of serotype homologous antibody in the enzyme-linked immunosorbent assay and the plaque-reduction neutralization test. Cross-reactive antibody titers were either several dilutions lower or not detectable. Sera from mice immunized with the tetravalent DEN subunit vaccine neutralized all 4 DEN viruses in the plaque-reduction neutralization test. The neutralizing antibody titers to each individual serotype were significantly greater than any cross-reactive neutralizing antibody titers induced by the monovalent vaccines, providing evidence that the tetravalent DEN recombinant subunit vaccine produced specific neutralizing antibody to all 4 serotypes of dengue virus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508393     DOI: 10.4269/ajtmh.2001.65.159

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  16 in total

1.  Serological differentiation of infections with dengue virus serotypes 1 to 4 by using recombinant antigens.

Authors:  Diana Ludolfs; Stefan Schilling; Jan Altenschmidt; Herbert Schmitz
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Potential role for Toll-like receptor 4 in mediating Escherichia coli maltose-binding protein activation of dendritic cells.

Authors:  Stefan Fernandez; Dupeh R Palmer; Monika Simmons; Peifang Sun; John Bisbing; Sasha McClain; Sachin Mani; Timothy Burgess; Vicky Gunther; Wellington Sun
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

3.  Maltose-binding protein isolated from Escherichia coli induces Toll-like receptor 2-mediated viability in U937 cells.

Authors:  Zhao Xiaoxia; Ni Weihua; Zhang Qingyong; Wang Fengli; Li Yingying; Sun Xiaxia; Liu Zhonghui; Tai Guixiang
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

4.  Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.

Authors:  Julia C Frei; Ariel S Wirchnianski; Jennifer Govero; Olivia Vergnolle; Kimberly A Dowd; Theodore C Pierson; Margaret Kielian; Mark E Girvin; Michael S Diamond; Jonathan R Lai
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

5.  Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.

Authors:  Thomas J Chambers; Yan Liang; Deborah A Droll; Jacob J Schlesinger; Andrew D Davidson; Peter J Wright; Xiaoshan Jiang
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

6.  An in-depth analysis of original antigenic sin in dengue virus infection.

Authors:  Claire M Midgley; Martha Bajwa-Joseph; Sirijitt Vasanawathana; Wannee Limpitikul; Bridget Wills; Aleksandra Flanagan; Emily Waiyaiya; Hai Bac Tran; Alison E Cowper; Pojchong Chotiyarnwong; Pojchong Chotiyarnwon; Jonathan M Grimes; Sutee Yoksan; Prida Malasit; Cameron P Simmons; Juthathip Mongkolsapaya; Gavin R Screaton
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

7.  Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.

Authors:  Claire M Midgley; Aleksandra Flanagan; Hai Bac Tran; Wanwisa Dejnirattisai; Kriangkrai Chawansuntati; Amonrat Jumnainsong; Wiyada Wongwiwat; Thaneeya Duangchinda; Juthathip Mongkolsapaya; Jonathan M Grimes; Gavin R Screaton
Journal:  J Immunol       Date:  2012-04-09       Impact factor: 5.422

8.  Next-generation dengue vaccines: novel strategies currently under development.

Authors:  Anna P Durbin; Stephen S Whitehead
Journal:  Viruses       Date:  2011-09-26       Impact factor: 5.048

9.  An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes.

Authors:  Saima Khanam; Pilankatta Rajendra; Navin Khanna; Sathyamangalam Swaminathan
Journal:  BMC Biotechnol       Date:  2007-02-15       Impact factor: 2.563

10.  Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology.

Authors:  Connor P O'Meara; Charles W Armitage; Marina C G Harvie; Peter Timms; Nils Y Lycke; Kenneth W Beagley
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.